Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

23
results for

"Chronic liver disease"

Article category

Keywords

Publication year

"Chronic liver disease"

Correspondence

Reply to Letter on “Sex-Specific Trends and Demographic vs Epidemiologic Drivers of Alcohol-Related Cirrhosis in the U.S., 2021–2040”
Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang
Received August 24, 2025  Accepted August 29, 2025  Published online September 1, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0948    [Accepted]
  • 1,569 View
  • 10 Download

Letter to the Editor

Comment on “High Steatosis-Associated Fibrosis Estimator Scores Predict Hepatocellular Carcinoma in Viral and Non-Viral Hepatitis and Metabolic Dysfunction-Associated Steatotic Liver Disease”
Prajnasini Satapathy, Rachana Mehta, Ranjana Sah
Received August 2, 2025  Accepted August 6, 2025  Published online August 8, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0875    [Accepted]
  • 2,086 View
  • 19 Download

Correspondences

Reply to the letter to the editor on “Re: “Sex Disparities in Alcohol-Associated Liver Disease and Subtype Differences in Alcohol-attributable Cancers in the United States”
Pojsakorn Danpanichkul, Luis Antonio Diaz, Juan Pablo Arab, Amit G. Singal, Ju Dong Yang
Received June 5, 2025  Accepted June 13, 2025  Published online June 17, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0594    [Accepted]

Citations

Citations to this article as recorded by  Crossref logo
  • Sex chromosomes/hormones and the tumor microenvironment of non-reproductive cancers
    Chun-Miao Zhang, Zhong-Bo Ge, Hai-Hong Zhou, Meng-Xiao Wei, Xin-Yuan Ding, Zhe-Zheng Lin, Ming-Yu Wang, Cai-Juan Bai
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Rising burden of steatotic liver disease in women of childbearing age and projections till 2035
    Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
    JHEP Reports.2025; : 101646.     CrossRef
  • 1,824 View
  • 17 Download
  • Crossref
Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
Received May 13, 2025  Accepted May 14, 2025  Published online May 15, 2025  
DOI: https://doi.org/10.3350/cmh.2025.0527    [Epub ahead of print]
  • 3,118 View
  • 12 Download

Original Article

Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States
Pojsakorn Danpanichkul, Yanfang Pang, Tanuj Mahendru, Primrose Tothanarungroj, Luis Antonio Díaz, Juan Pablo Arab, Pimtawan Jatupornpakdee, Mark D. Muthiah, Kwanjit Duangsonk, Won-Mook Choi, Daniel Q. Huang, Donghee Kim, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol 2025;31(3):1058-1070.
Published online April 11, 2025
DOI: https://doi.org/10.3350/cmh.2025.0169
Background/Aims
Harmful alcohol use is a substantial contributor to liver diseases, liver cancer, and extrahepatic neoplasms. Patterns of alcohol consumption have shifted over recent decades. This study evaluates trends in alcohol-associated liver disease (ALD) and alcohol-attributable cancers in the United States (US) from 2000 to 2021.
Methods
Using the methodological framework of the Global Burden of Disease Study 2021, we analyzed trends in incidence, prevalence, and mortality from ALD and alcohol-attributable cancers in the US.
Results
In 2021, there were 28,340 new cases of ALD, 227,730 prevalent cases, and 21,860 deaths attributed to ALD in the US. From 2000 to 2021, ALD incidence, prevalence, and mortality increased by 43%, 36%, and 79%, respectively. The age-standardized incidence and death rate of ALD rose disproportionately among females compared to males. For alcohol-attributable cancers, primary liver cancer, colorectal cancer, and esophageal cancer accounted for the largest share of deaths in 2021. Age-standardized death rates increased significantly for primary liver cancer (annual percent change [APC] 2.21%, 95% confidence interval [CI] 1.70–2.73%) and other pharyngeal cancer (APC 1.35%, 95% CI 1.08–1.62%).
Conclusions
The burden of ALD is substantial and continues to rise in the US, with a particularly notable increase among females. Mortality from alcohol-attributable cancers is also increasing, mainly driven by primary liver cancer and pharyngeal cancer. However, system-wise, gastrointestinal cancer had the highest death attributable to alcohol. These findings highlight the urgent need for public health strategies to tackle ALD, primary liver cancer, and alcoholattributable extrahepatic malignancies.

Citations

Citations to this article as recorded by  Crossref logo
  • Rising burden of steatotic liver disease in women of childbearing age and projections to 2035
    Youxin Wang, Ruiqiu Chen, Shi Yan Lee, Eunice X.X. Tan, Mark Muthiah, Zhou Yu, Margaret L.P. Teng, Jazleen Leo, Cheng Han Ng, Ashok Choudhury, Daniel Q. Huang
    JHEP Reports.2026; 8(1): 101646.     CrossRef
  • MetALD: new insights and unraveling therapeutic potential
    Yue Feng, PanShiLi Han, Tao Liu, YanHang Gao
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Sex Disparity in Major Adverse Liver Outcome and Major Adverse Cardiac Event in Alcohol‐Associated Liver Disease
    Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Mark D. Muthiah, Suthat Liangpunsakul
    Liver International.2025;[Epub]     CrossRef
  • Advancing Policy and Practice in Alcohol-Associated Liver Disease and Alcohol-Attributable Cancer: Correspondence to the editorial on “Rising Burden of Alcohol-Associated Liver Disease and Cancers: Insights into Sex Disparities and Policy Implications”
    Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Effect of varenicline on major adverse liver outcomes in alcohol‐associated liver disease: An exploratory analysis
    Pojsakorn Danpanichkul, Yanfang Pang, Donghee Kim, Thanathip Suenghataiphorn, Donghyun Ko, Andrew F. Ibrahim, Vitchapong Prasitsumrit, Kwanjit Duangsonk, Mazen Noureddin, Karn Wijarnpreecha, Suthat Liangpunsakul
    Alcohol, Clinical and Experimental Research.2025; 49(11): 2451.     CrossRef
  • Consumo de alcohol y cirrosis en mujeres: un riesgo subestimado
    P. Huerta, J.P. Arab, L.A. Díaz
    Revista de Gastroenterología de México.2025; 90(4): 509.     CrossRef
  • Alcohol use and cirrhosis in women: An underestimated risk
    P. Huerta, J.P. Arab, L.A. Díaz
    Revista de Gastroenterología de México (English Edition).2025; 90(4): 509.     CrossRef
  • 9,136 View
  • 147 Download
  • 5 Web of Science
  • Crossref

Editorial

Review

Liver fibrosis, cirrhosis, and portal hypertension

Sinusoidal communication in chronic liver disease
Albert Gibert-Ramos, María Andrés-Rozas, Raül Pastó, Pablo Alfaro-Retamero, Sergi Guixé-Muntet, Jordi Gracia-Sancho
Clin Mol Hepatol 2025;31(1):32-55.
Published online October 2, 2024
DOI: https://doi.org/10.3350/cmh.2024.0734
The liver sinusoid, mainly composed of liver sinusoidal endothelial cells, hepatic macrophages and hepatic stellate cells, shapes the hepatic vasculature and is key to maintaining liver homeostasis and function. During chronic liver disease (CLD), the function of sinusoidal cells is impaired, being directly involved in the progression of liver fibrosis, cirrhosis, and main clinical complications including portal hypertension and hepatocellular carcinoma. In addition to their roles in liver diseases pathobiology, sinusoidal cells’ paracrine communication or cross-talk is being studied as a mechanism of disease but also as a remarkable target for treatment. The aim of this review is to gather current knowledge of intercellular signalling in the hepatic sinusoid during the progression of liver disease. We summarise studies developed in pre-clinical models of CLD, especially emphasizing those pathways characterized in human-based clinically relevant models. Finally, we describe pharmacological treatments targeting sinusoidal communication as promising options to treat CLD and its clinical complications.

Citations

Citations to this article as recorded by  Crossref logo
  • Vasomics of the liver
    Chengyan Wang, Eric Felli, Jonathan Andrew Fallowfield, Christoph Frank Dietrich, Don Rockey, Jürgen Hennig, Gao-Jun Teng, Jordi Gracia-Sancho, Xiaolong Qi
    Gut.2025; 74(6): 1008.     CrossRef
  • Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells
    Enis Kostallari, Robert F. Schwabe, Adrien Guillot
    Cellular & Molecular Immunology.2025; 22(10): 1205.     CrossRef
  • Myeloid cells in chronic liver inflammation
    Dimitrios Patseas, Ahmed El-Masry, Zuobin Liu, Prakash Ramachandran, Evangelos Triantafyllou
    Cellular & Molecular Immunology.2025; 22(10): 1237.     CrossRef
  • Toll-like receptor 4-mediated inflammatory stimulation in Kupffer cell enhances arsenite-induced liver fibrosis by triggering hepatic stellate cell activation
    Qian Song, Meitong Zhou, Rui He, Heng Diao, Lili Fan, Chenglong Tu, Xiong Chen, Dapeng Wang
    Ecotoxicology and Environmental Safety.2025; 303: 118903.     CrossRef
  • The pathophysiological role of portal hypertension in metabolic dysfunction–associated steatotic liver disease
    Søren Møller, Sannia M.S. Sjöstedt, Lise Hobolth, Christian Mortensen, Nina Kimer
    Hepatology Communications.2025;[Epub]     CrossRef
  • Hepatocyte-derived extracellular vesicles promote endothelial dedifferentiation in chronic liver disease through the miR-153-3p-pyroptosis axis
    Laia Abad-Jordà, María Andrés-Rozas, Ana Martínez-Alcocer, Jessica Aspas, Yiliam Fundora, Sonia Fernández-Veledo, Carmen Peralta, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Jordi Gracia-Sancho
    Hepatology.2025;[Epub]     CrossRef
  • 8,314 View
  • 284 Download
  • 7 Web of Science
  • Crossref

Correspondence

Liver fibrosis, cirrhosis, and portal hypertension

  • 4,769 View
  • 62 Download

Special Issue

Liver fibrosis, cirrhosis, and portal hypertension

KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, Dae Won Jun, Seung Up Kim, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol 2024;30(Suppl):S5-S105.
Published online August 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0506

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”
    Hee Yeon Kim, Miyoung Choi, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(1): e48.     CrossRef
  • Non-Invasive Liver Fibrosis Test Using Shear Wave Elastography
    Ji Won Han
    The Korean Journal of Medicine.2025; 100(1): 26.     CrossRef
  • Influence of Sex in the Development of Liver Diseases
    Jie-Wen Zhang, Nan Zhang, Yi Lyu, Xu-Feng Zhang
    Seminars in Liver Disease.2025; 45(01): 015.     CrossRef
  • KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
    Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S1.     CrossRef
  • Noninvasive identification of metabolic dysfunction–associated steatohepatitis (INFORM MASH): a retrospective cohort and disease modeling study
    G. Craig Wood, Anthony Hoovler, Rakesh Luthra, Christopher D. Still, Hamzah Shariff, Matthew Still, Jonathan Hayes, Peter Benotti, Chioma Uzoigwe
    Expert Review of Gastroenterology & Hepatology.2025; 19(4): 427.     CrossRef
  • Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liv
    Ji Won Han, Dae Won Jun
    Clinical and Molecular Hepatology.2025; 31(2): e152.     CrossRef
  • The association between modified cardiometabolic index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study
    Yanjun Guo, Wei Su, Lulong Tao, Guoxin Zhang, Kun Wang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Future Perspectives of Liver Research in the Asia‐Pacific Region: Focus on Hepatitis B and C
    Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2025; 40(8): 1855.     CrossRef
  • Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients
    Guanlan Liu, Li Liu, Xing Yang, Qihao Wang, Mingqin Qian
    Journal of Clinical and Experimental Hepatology.2025; 15(6): 102610.     CrossRef
  • A Case Report of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) with Improved Cardiometabolic Risk Factors Following Treatment with Saenggangunbi-tang
    Eun Kyung Lee, Min Jeong Park, Youngchul Kim, Jang-Hoon Lee
    The Journal of Internal Korean Medicine.2025; 46(2): 303.     CrossRef
  • Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
    Hye Won Lee, Jae Seung Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Clinical and Molecular Hepatology.2025; 31(3): 1018.     CrossRef
  • Performance of APRI and FIB-4 Scores Compared to FibroScan: A Cross-Sectional Study in a Black Sub-Saharan African Population
    Jean-Bonny Nsumbu, Jean-Robert Makulo, Trésor Mutombo Tshiswaka, Christian Kisoka Lusunsi, Charles Nlombi Mbendi
    Hepatic Medicine: Evidence and Research.2025; Volume 17: 27.     CrossRef
  • Correspondence to editorial 1 on “Baveno VI-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2025;[Epub]     CrossRef
  • Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis
    Toshikazu Kohira, Satoshi Oeda, Erina Eto, Yoshihito Kubotsu, Misa Norita, Kaori Inoue, Nagisa Hara, Shotaro Noge, Kenichi Tanaka, Shigenobu Yoshimura, Noriko Oza, Keizo Anzai, Yuichiro Eguchi, Cheng Han Ng, Daniel Q. Huang, Mark D. Muthiah, Atsushi Kawag
    Scientific Reports.2025;[Epub]     CrossRef
  • Longitudinal Effects of Glecaprevir/Pibrentasvir on Liver Function, Fibrosis, and Hepatocellular Carcinoma Risk in Chronic Hepatitis C: A Prospective Multicenter Cohort Study
    Jung Hee Kim, Jae Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Yewan Park, Gi-Ae Kim, Seong Kyun Na, Young-Sun Lee, Jeong Han Kim
    Medicina.2025; 61(9): 1601.     CrossRef
  • Comment on ‘Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank’ by T. S. Lim et al.—Authors' Reply
    Tae Seop Lim, Sujin Kwon, Sung A Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
    Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
  • Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis
    Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2750.     CrossRef
  • Prospects of late-stage development agents in the treatment of metabolic dysfunction-associated steatohepatitis
    Brian Lee, Ussama Ghumman, Lisa D. Pedicone, Andres Gomez Aldana, Eric Lawitz
    Clinical and Molecular Hepatology.2025; 31(4): 1167.     CrossRef
  • Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis
    Huiru Jin, Mengfan Jiao, Chengxiao Yu, Tingting Ren, Qingling Chen, Zixing Dai, Erfu Xie, Longfeng Jiang, Yuwen Li
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Mistakes in the utilization of vibration-controlled transient elastography in the evaluation of liver fibrosis: a narrative review
    Madunil Anuk Niriella, Uditha Bandara Dassanayake, Charith Priyanga Madurapperuma, Indeewari Prathibha Wijesingha, Arjuna Priyadarshin De Silva, Hithnadura Janaka de Silva
    Expert Review of Gastroenterology & Hepatology.2025; : 1.     CrossRef
  • Enhanced Prediction of Hepatitis B Virus-Related Hepatocellular Carcinoma Using Age-male-albumin-bilirubin-platelet (aMAP) and Liver Stiffness Assessed by Vibration-controlled Transient Elastography
    Hye Yeon Chon, Hyung Joon Yim, Seok-Jae Heo, Su Jong Yu, Ja Kyung Kim, Sang Hoon Ahn, Grace Lai-Hung Wong, Jimmy Che-To Lai, Terry Cheuk-Fung Yip, Sang Gyune Kim, Yeon Seok Seo, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • A Novel Deep Learning Framework for Liver Fibrosis Staging and Etiology Diagnosis Using Integrated Liver–Spleen Elastography
    Kai Yang, Fei Chen, Aiping Tian, Long Deng, Xiaorong Mao
    Diagnostics.2025; 15(23): 2986.     CrossRef
  • Recent Trends in Noninvasive Tests for Assessing Hepatic Fibrosis in Patients with Chronic Liver Disease
    Jung Hwan Yu
    The Korean Journal of Medicine.2024; 99(5): 232.     CrossRef
  • Noninvasive Imaging Test to Assess Liver Fibrosis: Vibration-controlled Transient Elastography
    Mi Na Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 201.     CrossRef
  • Non-Invasive Test for Assessment of Liver Fibrosis in Chronic Hepatitis B
    Ye Ji Jun, Minjong Lee, Ho Soo Chun, Tae Hun Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 206.     CrossRef
  • Serological Markers to Assess Liver Fibrosis and Their Roles
    Beom Kyung Kim
    The Korean Journal of Gastroenterology.2024; 84(5): 195.     CrossRef
  • Liver Fibrosis Assessment in Chronic Liver Diseases Using Elastography: A Comprehensive Review of Vibration-Controlled Transient Elastography and Shear Wave Elastography
    Han Ah Lee
    Clinical Ultrasound.2024; 9(2): 70.     CrossRef
  • 13,266 View
  • 302 Download
  • 24 Web of Science
  • Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

Clinical applications of transient elastography
Kyu Sik Jung, Seung Up Kim
Korean J Hepatol 2012;18(2):163-173.
Published online June 26, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.2.163

Chronic liver disease represents a major public health problem, accounting for significant morbidity and mortality worldwide. As prognosis and management depend mainly on the amount and progression of liver fibrosis, accurate quantification of liver fibrosis is essential for therapeutic decision-making and follow-up of chronic liver diseases. Even though liver biopsy is the gold standard for evaluation of liver fibrosis, non-invasive methods that could substitute for invasive procedures have been investigated during past decades. Transient elastography (TE, FibroScan®) is a novel non-invasive method for assessment of liver fibrosis with chronic liver disease. TE can be performed in the outpatient clinic with immediate results and excellent reproducibility. Its diagnostic accuracy for assessment of liver fibrosis has been demonstrated in patients with chronic viral hepatitis; as a result, unnecessary liver biopsy could be avoided in some patients. Moreover, due to its excellent patient acceptance, TE could be used for monitoring disease progression or predicting development of liver-related complications. This review aims at discussing the usefulness of TE in clinical practice.

Citations

Citations to this article as recorded by  Crossref logo
  • FibrAIm – The machine learning approach to identify the early stage of liver fibrosis and steatosis
    Barbara Ginter-Matuszewska, Agnieszka Adamek, Maciej Majchrzak, Blazej Rozplochowski, Agata Zientarska, Arleta Kowala-Piaskowska, Piotr Lukasiak
    International Journal of Medical Informatics.2025; 197: 105837.     CrossRef
  • Detection of Hepatitis C Virus Infection in Patients Undergoing Open Heart Surgery in Childhood Prior to 1992: A Danish Nationwide Cross-Sectional Study
    Amalie Rosendahl, Louise Margrethe Kiær Uth, Nina Weis, Morten Smerup, Sabrina Gade Ellesøe
    Clinical Medicine Insights: Pediatrics.2025;[Epub]     CrossRef
  • Transient elastography for non-invasive assessment of liver fibrosis
    Piyush Manoria
    Future Health.2025; 2: 206.     CrossRef
  • Identifying liver cirrhosis in patients with chronic hepatitis B: an interpretable machine learning algorithm based on LSM
    Xueting Bai, Chunwen Pu, Wenchong Zhen, Yushuang Huang, Qian Zhang, Zihan Li, Yixin Zhang, Rongxuan Xu, Zhihan Yao, Wei Wu, Mei Sun, Xiaofeng Li
    Annals of Medicine.2025;[Epub]     CrossRef
  • Novel integrative models to predict the severity of inflammation and fibrosis in patients with drug-induced liver injury
    Yue Zhang, Chuan Lu, Jingying Xu, Qiqi Ma, Mei Han, Li Ying
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial
    Tugce Ozlu Karahan, Elvan Yilmaz Akyuz, Demet Yilmaz Karadag, Yusuf Yilmaz, Fatih Eren
    Life.2025; 15(5): 696.     CrossRef
  • Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C
    Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J
    Journal of Gastroenterology and Hepatology.2025; 40(10): 2568.     CrossRef
  • Sustained cardiovascular risk factor control is associated with reduced metabolic dysfunction-associated steatotic liver disease risk in SLE
    Nikolaos Papazoglou, Vassiliki Poulia, Elisavet Michailidou, George V Papatheodoridis, Petros P Sfikakis, Maria G Tektonidou
    Rheumatology.2025;[Epub]     CrossRef
  • The Relationship Between Non-Invasive Tests and Digital Pathology for Quantifying Liver Fibrosis in MASLD
    Xiaodie Wei, Lixia Qiu, Xinxin Wang, Chen Shao, Jing Zhao, Qiang Yang, Jun Chen, Meng Yin, Richard L. Ehman, Jing Zhang
    Diagnostics.2025; 15(19): 2475.     CrossRef
  • The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study
    Meryem Sahin Ozdemir, Yusuf Emre Ozdemir, Alperen Dogdas, Kanan Nuriyev, Ibrahim Volkan Senkal, Alper Gunduz, Esra Zerdali, Sabahattin Kaymakoglu, Bilgul Mete, Fehmi Tabak
    International Journal of STD & AIDS.2025;[Epub]     CrossRef
  • A chitinase-3-like protein-1-based nomogram for identification of significant liver fibrosis in the general population
    Piaopiao Jin, Nan Li, Chenbing Liu, Di Sheng, Lihong Qiu, Chenzhao Zhao, Zhong Liu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Primary Sclerosing Cholangitis
    Aalam Sohal, Sanya Kayani, Kris V. Kowdley
    Clinics in Liver Disease.2024; 28(1): 129.     CrossRef
  • Fibrotic Burden in Patients With Hepatitis B Virus–Related Cirrhosis Is Independently Associated With Poorer Kidney Outcomes
    Chan-Young Jung, Hui-Yun Jung, Hyung Woo Kim, Geun Woo Ryu, Jung Il Lee, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim
    The Journal of Infectious Diseases.2024; 229(1): 108.     CrossRef
  • Liver Elastography for the Detection of Methotrexate-Induced Liver Injury: A Retrospective Study
    Tim Brotherton, Maya Mahmoud, Sam Burton, Kamran Qureshi
    European Medical Journal.2024; : 118.     CrossRef
  • Evaluation of common carotid artery wall stiffness by shear wave elastography in smokers and non-smokers
    Kamber Goksu, Ahmet Vural, Ahmet N. Kahraman, Isil K. Aslan
    Tobacco Induced Diseases.2024; 22(March): 1.     CrossRef
  • Successful therapy with tenofovir disoproxil fumarate (TDF) in patients with chronic hepatitis B (CHB) does not guarantee amelioration of liver damage assessing by transient elastography. A retrospective - prospective multicenter study
    Hariklia Kranidioti, Konstantinos Zisimopoulos, Theodora Oikonomou, Theodoros Voulgaris, Spyros Siakavellas, Polixeni Agorastou, Melanie Deutsch, Christos Triantos, Ioannis Goulis, George Papatheodoridis, Spilios Manolakopoulos
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction‐associated steatohepatitis
    Shi Qi, Xiaodie Wei, Jinhan Zhao, Xinhuan Wei, Haiqing Guo, Jingxian Hu, Qiqige WuYun, Calvin Q. Pan, Nengwei Zhang, Jing Zhang
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1656.     CrossRef
  • Ultrasound Elastography: Basic Principles and Examples of Clinical Applications with Artificial Intelligence—A Review
    Maurizio Cè, Natascha Claudia D'Amico, Giulia Maria Danesini, Chiara Foschini, Giancarlo Oliva, Carlo Martinenghi, Michaela Cellina
    BioMedInformatics.2023; 3(1): 17.     CrossRef
  • Serum Gamma-Glutamyl Transpeptidase-to-Platelet Ratio as a Noninvasive Marker of Liver Fibrosis in Chronic Hepatitis B
    Subham Purkayastha, Ashish K Jha, Ravikant Kumar, Vishwa Mohan Dayal, Sanjeev K Jha
    Cureus.2023;[Epub]     CrossRef
  • Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
    Jung Hwan Yu, Han Ah Lee, Seung Up Kim
    Clinical and Molecular Hepatology.2023; 29(Suppl): S136.     CrossRef
  • ASPARTATE PLATELET RATIO INDEX AS A PREDICTOR OF SEVERITY OF FIBROSIS IN CHRONIC HEPATITS C
    KANNAN NARAYANAN, SUE ANN ZACHARIAH, SHEELA KURIAN V
    Asian Journal of Pharmaceutical and Clinical Research.2023; : 69.     CrossRef
  • Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B
    Hye Yeon Chon, Jae Seung Lee, Hye Won Lee, Ho Soo Chun, Beom Kyung Kim, Won Young Tak, Jun Yong Park, Young-Oh Kweon, Do Young Kim, Sang Hoon Ahn, Se Young Jang, Soo Young Park, Seung Up Kim
    Clinical Gastroenterology and Hepatology.2022; 20(4): e794.     CrossRef
  • Long‐term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B
    Young Eun Chon, Seung Up Kim, Yeon Seok Seo, Hye Won Lee, Han Ah Lee, Mi Na Kim, Yun Ho Roh, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Won Young Tak, Soo Young Park, Beom Kyung Kim
    Journal of Gastroenterology and Hepatology.2022; 37(1): 200.     CrossRef
  • Future Directions in EndoHepatology
    Ahmad Najdat Bazarbashi, Lolwa Al-Obaid, Marvin Ryou
    Techniques and Innovations in Gastrointestinal Endoscopy.2022; 24(1): 98.     CrossRef
  • Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus
    Ozge Yetginoglu, Dilek Barutcu Atas, Yusuf Yilmaz, Arzu Velioglu, Hakki Arikan, Fatma Alibaz-Oner, Haner Direskeneli, Serhan Tuglular, Ebru Asicioglu
    Lupus.2022; 31(6): 723.     CrossRef
  • Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria
    Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Young Jang, Soo Young Park, Hyun Woong Lee, Chun Kyon Lee, Seung Up Kim
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Diagnostic accuracy of apparent diffusion coefficient values combined with γ-glutamyl transpeptidase-to-platelet ratio parameters for predicting hepatitis B-related fibrosis
    Xingxiang Liu, Jian Zhou, Liyao Zhu, Xin Zhang, Feng Li
    Clinics and Research in Hepatology and Gastroenterology.2022; 46(8): 101968.     CrossRef
  • Diagnostic accuracy of transient elastography in diagnosing clinically significant portal hypertension in patients with chronic liver disease: a systematic review and meta-analysis
    Ashish Kumar, Hitoshi Maruyama, Anil Arora, Praveen Sharma, Shrihari Anil Anikhindi, Naresh Bansal, Mandhir Kumar, Piyush Ranjan, Munish Sachdeva, Shivam Khare
    Journal of Medical Ultrasonics.2022; 49(3): 333.     CrossRef
  • Magnetic resonance imaging improves stratification of fibrosis and steatosis in patients with chronic liver disease
    Han Ah Lee, Seung-seob Kim, Jin-Young Choi, Yeon Seok Seo, Beom Jin Park, Ki Choon Sim, Seung Up Kim
    Abdominal Radiology.2022; 47(11): 3733.     CrossRef
  • Magnetic Resonance Elastography Versus Transient Elastography in the Prediction of Complications After Resection for Hepatocellular Carcinoma
    Jae Seok Bae, Dong Ho Lee, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Haeryoung Kim, Kyung Bun Lee, Yunhee Choi
    Annals of Surgery.2022; 276(5): e466.     CrossRef
  • The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease
    Tugce OZLU, Yusuf YILMAZ, Fatma E. GUNES
    Minerva Gastroenterology.2022;[Epub]     CrossRef
  • Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study
    Oidov Baatarkhuu, Jae Seung Lee, Jazag Amarsanaa, Do Young Kim, Sang Hoon Ahn, Nyamsuren Naranzul, Damba Enkhtuya, Nagir Choijamts, Purev Batbayar, Radnaa Otgonbayar, Bat-Ulzii Saruul, Chuluunbaatar Gantuul, Baljinnyam Gegeebadrakh, Narangerel Tuvshinbaya
    Clinical and Molecular Hepatology.2021; 27(1): 125.     CrossRef
  • Association of α-fetoprotein levels with liver stiffness measurement in outpatients with chronic hepatitis B
    Juan Wang, Pengpeng Zhang, Juan Liao, Yan Zhu, Xiaoli Liu, Hong Tang
    Bioscience Reports.2021;[Epub]     CrossRef
  • Artificial Intelligence in Imaging of Chronic Liver Diseases
    Carl F. Sabottke, Bradley M. Spieler, Ahmed W. Moawad, Khaled M. Elsayes
    Magnetic Resonance Imaging Clinics of North America.2021; 29(3): 451.     CrossRef
  • Risk assessment of hepatocellular carcinoma and liver‐related events using ultrasonography and transient elastography in patients with chronic hepatitis B
    Sung Hwan Yoo, Tae Seop Lim, Hyun Woong Lee, Ja Kyung Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jung Il Lee, Kwan Sik Lee, Seung Up Kim
    Journal of Viral Hepatitis.2021; 28(10): 1362.     CrossRef
  • The role of liver and spleen elastography in advanced chronic liver disease
    Elton DAJTI, Giovanni MARASCO, Federico RAVAIOLI, Luigina V. ALEMANNI, Benedetta ROSSINI, Luigi COLECCHIA, Amanda VESTITO, Davide FESTI, Antonio COLECCHIA
    Minerva Gastroenterology.2021;[Epub]     CrossRef
  • The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
    Zobair M. Younossi, Quentin M. Anstee, Vincent Wai-Sun Wong, Michael Trauner, Eric J. Lawitz, Stephen A. Harrison, Marianne Camargo, Kathryn Kersey, G. Mani Subramanian, Robert P. Myers, Maria Stepanova
    Gastroenterology.2021; 160(5): 1608.     CrossRef
  • Liver Stiffness-Based Risk Prediction Model for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
    Jae Seung Lee, Dong Hyun Sinn, Soo Young Park, Hye Jung Shin, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Joo Hyun Oh, Jung Il Lee, Seung Up Kim
    Cancers.2021; 13(18): 4567.     CrossRef
  • Sarcopenia assessed using bioimpedance analysis is associated independently with significant liver fibrosis in patients with chronic liver diseases
    Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    European Journal of Gastroenterology & Hepatology.2020; 32(1): 58.     CrossRef
  • Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy
    Mi Na Kim, Ju Ho Lee, Young Eun Chon, Yeonjung Ha, Seong Gyu Hwang
    European Journal of Gastroenterology & Hepatology.2020; 32(3): 433.     CrossRef
  • Impact of chronic HCV treatment on quality of life of patients with metabolic disorders in context of immunological disturbances
    Agata Kierepa, Aleksandra Witkowska, Mariusz Kaczmarek, Krzysztof Książek, Justyna Mikuła-Pietrasik, Jan Żeromski, Arleta Kowala-Piaskowska, Iwona Mozer-Lisewska
    Scientific Reports.2020;[Epub]     CrossRef
  • Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study
    Edford Sinkala, Michael Vinikoor, Alice Miyanda Siyunda, Kanekwa Zyambo, Ellen Besa, Bright Nsokolo, Gilles Wandeler, Graham R. Foster, Paul Kelly
    Heliyon.2020; 6(7): e04534.     CrossRef
  • Association between liver fibrosis and appendicular skeletal muscle mass during antiviral therapy in chronic hepatitis B
    Kyung Hyun Kim, Dong Jin Joo, Yong-ho Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
    Digestive and Liver Disease.2020; 52(11): 1338.     CrossRef
  • Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Step Forward for Better Evaluation Using Ultrasound Elastography
    Monica Lupsor-Platon, Teodora Serban, Alexandra-Iulia Silion, Alexandru Tirpe, Mira Florea
    Cancers.2020; 12(10): 2778.     CrossRef
  • Fibrosis‐matched outcomes between chronic hepatitis B patients with drug‐induced virological response and inactive carriers
    Hye Soo Kim, Oidov Baatarkhuu, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang‐Hyub Han, Beom Kyung Kim, Seung Up Kim
    Liver International.2019; 39(1): 81.     CrossRef
  • Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
    Paul Manka, Amos Zeller, Wing-Kin Syn
    Drugs.2019; 79(9): 903.     CrossRef
  • Spleen Stiffness Differentiates Between Acute and Chronic Liver Damage and Predicts Hepatic Decompensation
    Phil Meister, Alexander Dechêne, Matthias Büchter, Julia Kälsch, Guido Gerken, Ali Canbay, Christoph Jochum
    Journal of Clinical Gastroenterology.2019; 53(6): 457.     CrossRef
  • Abdominal Obesity as a Predictive Factor of Nonalcoholic Fatty Liver Disease Assessed by Ultrasonography and Transient Elastography in Polycystic Ovary Syndrome and Healthy Women
    Siriluk Tantanavipas, Orawin Vallibhakara, Abhasnee Sobhonslidsuk, Sith Phongkitkarun, Sakda Arj-Ong Vallibhakara, Kwannapa Promson, Areepan Sophonsritsuk
    BioMed Research International.2019; 2019: 1.     CrossRef
  • Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up
    Pegah Khoshpouri, Roya Rezvani Habibabadi, Bita Hazhirkarzar, Sanaz Ameli, Maryam Ghadimi, Mounes Aliyari Ghasabeh, Christine O. Menias, Amy Kim, Zhiping Li, Ihab R. Kamel
    RadioGraphics.2019; 39(7): 1938.     CrossRef
  • Liver Fibrosis: A Clinical Update
    Lindsey C. Shipley, Page D. Axley, Ashwani K. Singal
    EMJ Hepatology.2019; : 105.     CrossRef
  • Serum S100 calcium binding protein A4 improves the diagnostic accuracy of transient elastography for assessing liver fibrosis in hepatitis B
    Li-Bo Yan, Qing-Bo Zhang, Xia Zhu, Min He, Hong Tang
    Clinics and Research in Hepatology and Gastroenterology.2018; 42(1): 64.     CrossRef
  • Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus‐related advanced fibrosis or cirrhosis
    Byung Seok Kim, Yeon Seok Seo, Young Seok Kim, Chang Hyeong Lee, Han Ah Lee, Soon Ho Um, Jeong‐Ju Yoo, Sang Gyune Kim, Sang Jun Suh, Young Kul Jung, Sang Hoon Ahn, Kwang‐Hyub Han, Hyung Joon Yim, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2018; 33(2): 503.     CrossRef
  • The gamma-glutamyl transferase to platelet ratio and the FIB-4 score are noninvasive markers to determine the severity of liver fibrosis in chronic hepatitis B infection
    J Lee, MY Kim, SH Kang, J Kim, Y Uh, KJ Yoon, HS Kim
    British Journal of Biomedical Science.2018; 75(3): 128.     CrossRef
  • Risk-stratified screening for chronic liver disease using vibration-controlled transient elastography (Fibroscan)
    Aquiline Chivinge, Rebecca Harris, Neil Guha, Guruprasad Aithal, Martin James, Stephen Ryder, Emilie Wilkes, Mary Holmes
    Gastrointestinal Nursing.2018; 16(5): S15.     CrossRef
  • Comparison of acoustic radiation force impulse elastography and transient elastography for prediction of hepatocellular carcinoma recurrence after radiofrequency ablation
    Jun Sik Yoon, Yu Rim Lee, Young-Oh Kweon, Won Young Tak, Se Young Jang, Soo Young Park, Keun Hur, Jung Gil Park, Hye Won Lee, Jae Min Chun, Young Seok Han, Won Kee Lee
    European Journal of Gastroenterology & Hepatology.2018; 30(10): 1230.     CrossRef
  • Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis
    Ji Hyun Kim, Minjong Lee, Seung Woo Park, Myungho Kang, Minjeong Kim, Sang Hoon Lee, Tae Suk Kim, Jin Myung Park, Dae Hee Choi
    Medicine.2018; 97(48): e13438.     CrossRef
  • A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension
    Myung-Won You, Kyung Won Kim, Junhee Pyo, Jimi Huh, Hyoung Jung Kim, So Jung Lee, Seong Ho Park
    Ultrasound in Medicine & Biology.2017; 43(1): 59.     CrossRef
  • Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis
    Young Eun Chon, Jun Yong Park, Sung-Min Myoung, Kyu Sik Jung, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
    American Journal of Gastroenterology.2017; 112(6): 882.     CrossRef
  • Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy
    Mona El-Hariri, Ahmed G. Abd El Megid, Tamer F. Taha Ali, Mohamed Hassany
    The Egyptian Journal of Radiology and Nuclear Medicine.2017; 48(2): 329.     CrossRef
  • 2-dimensional shear wave elastography: Interobserver agreement and factors related to interobserver discrepancy
    Kibo Yoon, Woo Kyoung Jeong, Yongsoo Kim, Min Yeong Kim, Tae Yeob Kim, Joo Hyun Sohn, Antoine Nordez
    PLOS ONE.2017; 12(4): e0175747.     CrossRef
  • Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation
    Yu Rim Lee, Soo Young Park, Seung Up Kim, Se Young Jang, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Keun Hur
    Journal of Gastroenterology and Hepatology.2017; 32(5): 1079.     CrossRef
  • Gamma‐glutamyl transpeptidase‐to‐platelet ratio is an independent predictor of hepatitis B virus‐related liver cancer
    Yong Eun Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Sojung Han, Mi Young Jeon, Ja Yoon Heo, Kijun Song, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2017; 32(6): 1221.     CrossRef
  • Utility of Transient Elastography in Estimating Hepatic Iron Concentration in Comparison to Magnetic Resonance Imaging in Patients Who are Transfusion-Dependent: A Canadian Center Experience
    George Ou, Hin Hin Ko, Pari Tiwari, Navdeep Sandhu, Cherry Galorport, Terry Lee, Hatoon Ezzat
    Hemoglobin.2017; 41(1): 21.     CrossRef
  • Chronic hepatitis B patients with high liver fibrosis levels should receive antiviral treatment
    Xu Li, Qinglong Jin, Hongqin Xu, Zetian Zhang, Hongjie Zhou, Dongqing Yan, Dongmei Li, Pujun Gao, Junqi Niu
    Experimental and Therapeutic Medicine.2017; 13(6): 3624.     CrossRef
  • Is carbohydrate deficient transferrin (CDT) a useful biomarker to identify alcohol abuse in advanced liver fibrosis?
    Jong-Han Lee, Gil sung Yoo, Seong Hee Kang, Young Uh
    Alcohol and Alcoholism.2017; 52(6): 749.     CrossRef
  • KASL clinical practice guidelines: management of hepatitis C

    Clinical and Molecular Hepatology.2016; 22(1): 76.     CrossRef
  • Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease
    Bong Jin Ko, Young Seok Kim, Sang Gyune Kim, Jung Hwan Park, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim, Sun Mi Kim, Young Don Kim, Gab Jin Cheon, Bo Ra Lee
    Gut and Liver.2016; 10(5): 818.     CrossRef
  • Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
    Hye Won Lee, Soo Young Park, Seung Up Kim, Jae Young Jang, Hana Park, Ja Kyung Kim, Chun Kyon Lee, Young Eun Chon, Kwang-Hyub Han, Han-Chieh Lin
    PLOS ONE.2016; 11(6): e0157358.     CrossRef
  • Non-alcoholic Fatty Liver Disease (NAFLD) and Significant Hepatic Fibrosis Defined by Non-invasive Assessment in Patients with Type 2 Diabetes
    Abhasnee Sobhonslidsuk, Akharawit Pulsombat, Piyaporn Kaewdoung, Supanna Petraksa
    Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1789.     CrossRef
  • Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography–defined subclinical cirrhosis
    Mi Na Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Ki Jun Song, Young Nyun Park, Kwang‐Hyub Han
    Hepatology.2015; 61(6): 1851.     CrossRef
  • Liver stiffness measurement for risk assessment of hepatocellular carcinoma
    Akihisa Tatsumi, Shinya Maekawa, Mitsuaki Sato, Nobutoshi Komatsu, Mika Miura, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto, Nobuyuki Enomoto
    Hepatology Research.2015; 45(5): 523.     CrossRef
  • Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease
    Rabia Ergelen, Umit Akyuz, Yucel Aydin, Fatih Eren, Yusuf Yilmaz
    European Journal of Gastroenterology & Hepatology.2015; 27(6): 667.     CrossRef
  • Evaluation of portal hypertension by real‐time shear wave elastography in cirrhotic patients
    Tae Yeob Kim, Woo Kyoung Jeong, Joo Hyun Sohn, Jinoo Kim, Min Yeong Kim, Yongsoo Kim
    Liver International.2015; 35(11): 2416.     CrossRef
  • Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification
    Seng Chan You, Kwang Joon Kim, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han
    Journal of Gastroenterology and Hepatology.2015; 30(10): 1536.     CrossRef
  • Noninvasive Evaluation of Liver Fibrosis Using Real‐time Tissue Elastography and Transient Elastography (FibroScan)
    Fankun Meng, Ying Zheng, Qi Zhang, Xiaojie Mu, Xiaoluan Xu, Haiying Zhang, Lei Ding
    Journal of Ultrasound in Medicine.2015; 34(3): 403.     CrossRef
  • Assessment of Substantial Liver Fibrosis by Real‐time Shear Wave Elastography in Methotrexate‐Treated Patients With Rheumatoid Arthritis
    Tae Yeob Kim, Ji Yeoun Kim, Joo Hyun Sohn, Hye-Soon Lee, So-Young Bang, Yongsoo Kim, Min Yeong Kim, Woo Kyoung Jeong
    Journal of Ultrasound in Medicine.2015; 34(9): 1621.     CrossRef
  • Factors associated with significant liver fibrosis assessed using transient elastography in general population
    Seng Chan You
    World Journal of Gastroenterology.2015; 21(4): 1158.     CrossRef
  • Prevalence in vulnerable population of liver fibrosis identified by transient elastography
    Norberto Chávez-Tapia, Jorge Torres-Sánchez, Juan Romero-Flores, Paulina Álvarez-Quiroz, Sandra Ramírez-Álvarez, Eva Juárez-Hernández, José Pérez-Jáuregui, Nahum Méndez-Sánchez, Misael Uribe
    Annals of Hepatology.2015; 14(4): 524.     CrossRef
  • ELF-test less accurately identifies liver cirrhosis diagnosed by liver stiffness measurement in non-Asian women with chronic hepatitis B
    S. Harkisoen, G.J. Boland, J.A.R. van den Hoek, K.J. van Erpecum, A.I.M. Hoepelman, J.E. Arends
    Journal of Clinical Virology.2014; 61(4): 503.     CrossRef
  • KASL clinical practice guidelines: Management of Hepatitis C

    Clinical and Molecular Hepatology.2014; 20(2): 89.     CrossRef
  • Risk Assessment of Liver-related Events Using Transient Elastography in Patients With Chronic Hepatitis B Receiving Entecavir
    Mi Na Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Chae Yoon Chon, Sang Hoon Ahn
    Journal of Clinical Gastroenterology.2014; 48(3): 272.     CrossRef
  • Clinically Severe Portal Hypertension: Role of Multi-detector Row CT Features in Diagnosis
    Ji Young Lee, Tae Yeob Kim, Woo Kyoung Jeong, Yongsoo Kim, Jinoo Kim, Kyoung Won Kim, Young Hwan Kim, Joo Hyun Sohn
    Digestive Diseases and Sciences.2014; 59(9): 2333.     CrossRef
  • Longitudinal change of liver stiffness by transient elestography in chronic hepatitis B patients treated with nucleos(t)ide analogue
    Won Jang, Sung In Yu, Dong Hyun Sinn, Sang Hoon Park, Hyun Park, Ji Young Park, Tae Joo Jeon, Tae Hoon Oh, Won Chang Shin, Won-Choong Choi
    Clinics and Research in Hepatology and Gastroenterology.2014; 38(2): 195.     CrossRef
  • Non-invasive prediction of development of hepatocellular carcinoma using transient elastography in patients with chronic liver disease
    Mi Sung Park, Kwang-Hyub Han, Seung Up Kim
    Expert Review of Gastroenterology & Hepatology.2014; 8(5): 501.     CrossRef
  • Acoustic Radiation Force Impulse (ARFI) and Transient Elastography (TE) for evaluation of liver fibrosis in HIV-HCV co-infected patients
    Nora Frulio, Hervé Trillaud, Paul Perez, Julien Asselineau, Marianne Vandenhende, Mojgan Hessamfar, Fabrice Bonnet, Florent Maire, Jean Delaune, Victor De Ledinghen, Philippe Morlat
    BMC Infectious Diseases.2014;[Epub]     CrossRef
  • Nondiseased Liver Stiffness Measured by Shear Wave Elastography
    Seung Woo Cha, Woo Kyoung Jeong, Yongsoo Kim, Min Yeong Kim, Jinoo Kim, Soo Yeon Kim, Jeong Ah Ryu, Tae Yeob Kim, Joo Hyun Sohn, Young Hwan Kim
    Journal of Ultrasound in Medicine.2014; 33(1): 53.     CrossRef
  • Egy-Score Predicts Severe Hepatic Fibrosis and Cirrhosis in Egyptians With Chronic Liver Diseases: A Pilot Study
    Mohamed A. Alboraie, Mahmoud E. Afifi, Fathy G. Elghamry, Helmy A. Shalaby, Gamal E. Elshennawy, Ahmed A. Abdelaziz, Mohamed U. Shaheen, Amany R. Abo El-Seoud
    Hepatitis Monthly.2013;[Epub]     CrossRef
  • KASL Clinical Practice Guidelines: Management of Alcoholic Liver Disease

    Clinical and Molecular Hepatology.2013; 19(3): 216.     CrossRef
  • Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents
    Emily Yiping Gan, Wei-Sheng Chong, Hong Liang Tey
    BioDrugs.2013; 27(4): 359.     CrossRef
  • Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific region
    Mi Na Kim, Beom Kyung Kim, Kwang-Hyub Han
    Journal of Gastroenterology.2013; 48(6): 681.     CrossRef
  • Clinical Benefit of Liver Stiffness Measurement at 3 Months after Kasai Hepatoportoenterostomy to Predict the Liver Related Events in Biliary Atresia
    Seung Min Hahn, Seung Kim, Kook In Park, Seok Joo Han, Hong Koh, James Fung
    PLoS ONE.2013; 8(11): e80652.     CrossRef
  • 15,792 View
  • 130 Download
  • Crossref
Original Articles
A study of the awareness of chronic liver diseases among Korean adults
Dae Won Jun, Yong Kyun Cho, Joo Hyun Sohn, Chang Hyeong Lee, Seok Hyun Kim, Jong Ryul Eun
Korean J Hepatol 2011;17(2):99-105.
Published online June 23, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.2.99
Background/Aims

Chronic liver disease is closely associated with lifestyle, and public enlightenment of the lifestyle factors is important in reducing prevalence of chronic liver disease. The KASL (Korean Association for the Study of the Liver) conducted a survey of basic information and epidemiological data regarding chronic liver diseases.

Methods

A survey of chronic liver disease involving a total of 2,794 respondents was conducted. The respondents included patients and their guardians, visitors for health check-ups, and online pollees who completed a questionnaire on the awareness of fatty liver or chronic liver disease.

Results

Of the entire cohort, 854 (39.7%) said they have had or still have fatty liver or an elevated transaminase level (>40 IU/L), but only 23.4% of the respondents had visited a hospital. It was found that 35% of healthy subjects and 45% of patients and their guardians misunderstood hepatitis B as the hereditary disesase. Furthermore, 26% of the subjects responded that patients with inactive hepatitis B do not require regular follow-up. While 17.9% answered that it is not too late to test for liver cancer when symptoms arise, 38.8% believed that liver transplant in liver cancer patients has a low success rate and is thus not recommended.

Conclusions

Despite the inundation of information and widespread media advertising, the awareness of chronic liver disease is unsatisfactory among Korean adults. Systematic nationwide studies are needed to obtain data and information regarding the prevalence of chronic liver disease and patterns of use of the health-care system.

Citations

Citations to this article as recorded by  Crossref logo
  • Understanding Hepatitis B Knowledge, Attitudes, and Stigma in the Korean Community in Australia
    Youngnam Baek, Robyn Horwitz, Loren Brener, Sylvester Okeke, Tim Broady, Carla Treloar, Elena Cama
    Journal of Racial and Ethnic Health Disparities.2025;[Epub]     CrossRef
  • Exploring the knowledge and attitudes towards metabolic dysfunction associated fatty liver disease (MAFLD): Validation and correlations of MAFLD-knowledge questionnaire and MAFLD-attitude questionnaire
    Samah Al Tawil, Mohamad Abdelkhalik, Adam El Fouani, Nour Allakiss, Lama Mattar, Wissam H. Faour, Rajaa Chatila
    Heliyon.2024; 10(22): e40217.     CrossRef
  • Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
    Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, Pietro Lampertico, Maria Buti, Claude B. Sirlin, Mindie H. Nguyen, Rohit Loomba
    Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 797.     CrossRef
  • Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A large‐scale Asian study
    Mei Hsuan Lee, Sang Hoon Ahn, Henry L. Y. Chan, Asad Choudhry, Rino Alvani Gani, Rosmawati Mohamed, Janus P. Ong, Akash Shukla, Chee Kiat Tan, Tawesak Tanwandee, Pham Thi Thu Thuy, Boon Leong Neo, Venus Tsang, Jin Youn, Shikha Singh
    Journal of Viral Hepatitis.2022; 29(2): 156.     CrossRef
  • The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database
    Naim Alkhouri, Ashraf Almomani, Phuc Le, Julia Y. Payne, Imad Asaad, Celine Sakkal, Miriam Vos, Mazen Noureddin, Prabhat Kumar
    BMC Gastroenterology.2022;[Epub]     CrossRef
  • Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study
    Ammal M. Metwally, Dalia M. Elmosalami, Hazem Elhariri, Lobna A. El Etreby, Ahmed Aboulghate, Marwa M. El-Sonbaty, Amira Mohsen, Rehan M. Saleh, Ghada A. Abdel-Latif, Sahar Samy, Sherif E. El Deeb, Asmaa M. Fathy, Mohab M. Salah, Mohamed A. Abdel Mawla, H
    PLOS ONE.2021; 16(2): e0242257.     CrossRef
  • Self-testing for liver disease – response to an online liver test questionnaire
    Achim Kautz, Rebecca Dorner, Christoph Antoni, Matthias Ebert, Andreas Teufel
    Scandinavian Journal of Gastroenterology.2020; 55(1): 67.     CrossRef
  • Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals
    Saikat Banerjee, Sampada Kumar Dash
    Health Marketing Quarterly.2018; 35(2): 134.     CrossRef
  • Granulocyte colony stimulating factor treatment in non-alcoholic fatty liver disease: beyond marrow cell mobilization
    Ho Hyun Nam, Dae Won Jun, Kiseok Jang, Waqar Khalid Saeed, Jai Sun Lee, Hyeon Tae Kang, Yeon Ji Chae
    Oncotarget.2017; 8(58): 97965.     CrossRef
  • Usefulness of Ultrasonographic Scoring System in Diagnosis of Alcoholic Cirrhosis
    Kyoung Min Moon, Soon Koo Baik
    Clinical Ultrasound.2016; 1(2): 92.     CrossRef
  • Hepatoprotective effects ofRubus coreanusmiquel concentrates on liver injuries induced by carbon tetrachloride in rats
    Hyun-Jung Chae, Jung-Eun Yim, Kyung-Ah Kim, Jong-Hee Chyun
    Nutrition Research and Practice.2014; 8(1): 40.     CrossRef
  • Efficacy and Safety of Human Placental Extract for Alcoholic and Nonalcoholic Steatohepatitis: An Open-Label, Randomized, Comparative Study
    Jin Young Choi, Kyeheui Lee, Seung Min Lee, Sun Hong Yoo, Seong Gyu Hwang, Jong Young Choi, Sang Wook Lee, Jae Seok Hwang, Kyoung Kon Kim, Hee Cheol Kang, Gab Jin Cheon, Young Min Park
    Biological and Pharmaceutical Bulletin.2014; 37(12): 1853.     CrossRef
  • Ultrasonographic scoring system score versus liver stiffness measurement in prediction of cirrhosis
    Kyoung Min Moon, Gaeun Kim, Soon Koo Baik, Eunhee Choi, Moon Young Kim, Hyoun A Kim, Mee Yon Cho, Seung Yong Shin, Jung Min Kim, Hong Jun Park, Sang Ok Kwon, Young Woo Eom
    Clinical and Molecular Hepatology.2013; 19(4): 389.     CrossRef
  • Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis
    John FP Bridges, Liming Dong, Gisselle Gallego, Barri M Blauvelt, Susan M Joy, Timothy M Pawlik
    BMC Health Services Research.2012;[Epub]     CrossRef
  • 10,417 View
  • 56 Download
  • Crossref
Clinical factors influencing Liver stiffness as measured by transient elastography (FibroscanⓇ) in patients with chronic Liver disease
Rack Cheon Bae, M.D., Han Jin Cho, M.D., Jong Taek Oh, M.D., Eung Kap Lee, M.D., Jun Heo, M.D., Keun Young Shin, M.D., Soo Young Park, M.D., Min Kyu Jeong, M.D., Seong Woo Jeon, M.D., Chang Min Cho, M.D., Won Young Tak, M.D., Young Oh Kweon, M.D.
Korean J Hepatol 2010;16(2):123-130.
Published online June 25, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.2.123
Background/Aims
Transient elastography as performed using the FibroscanⓇ is a useful noninvasive method for evaluating hepatic fibrosis. However, recent studies have found that liver stiffness measurement (lSM) values are inappropriately elevated in acute hepatitis or in the acute flare state of chronic hepatitis, suggesting that the lSM value obtained by the FibroscanⓇ is not a reliable marker for fibrosis. We retrospectively evaluated the clinical factors influencing the lSM value obtained using transient elastography as performed using the FibroscanⓇ in patients with chronic liver disease. Methods: A total of 298 patients who were followed in Kungpook National University Hospital from November 2007 to May 2008 due to previously established liver cirrhosis or chronic liver disease were investigated using the FibroscanⓇ, laboratory test, ultrasound, and/or abdominal computed tomography. Results: The 298 patients were aged 47.8±12.9 years (mean±SD). The cut-off value for a diagnosis of liver cirrhosis was 12.5 kPa (as used in previous studies). Thirty-six patients (15%) and 202 patients (85%) with chronic liver disease without clinical manifestation of cirrhosis had lSMs of >12.5 kPa and <12.5 kPa, respectively. Multivariate analysis revealed that lSM values were unusually increased in patients with chronic liver disease who were older (P=0.007) or who had increased gamma gultamyltranspetidase (GGT) (P=0.022), decreased albumin (P=0.015), or increased total bilirubin (P=0.009). Conclusions: This study reveals that age, GGT, and albumin are clinical factors influencing lSM values. This reinforces the need to interpret lSM values in the context of a defined diagnosis, biochemical data, radiologic examination, and other clinical findings.

Citations

Citations to this article as recorded by  Crossref logo
  • A sequential approach using the age‐adjusted fibrosis‐4 index and vibration‐controlled transient elastography to detect advanced fibrosis in Korean patients with non‐alcoholic fatty liver disease
    Dong Hyeon Lee, Se Un Sung, Yun Kyu Lee, Ik Hyeon Lim, Heejoon Jang, Sae Kyoung Joo, Jeong Hwan Park, Mee Soo Chang, Young Ho So, Won Kim
    Alimentary Pharmacology & Therapeutics.2022; 55(8): 994.     CrossRef
  • The Diagnostic value of FibroScan for the degree of liver fibrosis in patients with ALT<2×ULN chronic hepatitis B
    Shi Wenjian, Che Tuanjie, Li Chun, Li Caidong, Zhang Yan, Li Xiaoling, jia Zhong, Wan Hong
    Global Journal of Medical and Clinical Case Reports.2020; 7(1): 030.     CrossRef
  • Analysis on Usefulness of Non-invasive Liver Fibrosis Evaluation Method according to the Liver Disease : Focused on H ep atitis C p atients
    Nam Ji-Hee, Kim Jung-Hoon
    Journal of Radiological Science and Technology.2019; 42(5): 345.     CrossRef
  • Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease
    Bong Jin Ko, Young Seok Kim, Sang Gyune Kim, Jung Hwan Park, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim, Sun Mi Kim, Young Don Kim, Gab Jin Cheon, Bo Ra Lee
    Gut and Liver.2016; 10(5): 818.     CrossRef
  • Liver stiffness and portal blood flow modifications induced by a liquid meal consumption: pathogenetic mechanisms and clinical relevance
    Michele Barone, Andrea Iannone, Natale Daniele Brunetti, Francesco Sebastiani, Onofrio Cecere, Elsa Berardi, Gianfranco Antonica, Alfredo Di Leo
    Scandinavian Journal of Gastroenterology.2015; 50(5): 560.     CrossRef
  • The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
    In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
    Clinical and Molecular Hepatology.2015; 21(1): 32.     CrossRef
  • Early on‐treatment change in liver stiffness predicts development of liver‐related events in chronic hepatitis B patients receiving antiviral therapy
    Beom K. Kim, Hyun J. Oh, Jun Y. Park, Do Y. Kim, Sang H. Ahn, Kwang H. Han, Yehyun Park, Eun J. Yoo, Young N. Park, Seung U. Kim
    Liver International.2013; 33(2): 180.     CrossRef
  • Clinical applications of transient elastography
    Kyu Sik Jung, Seung Up Kim
    Clinical and Molecular Hepatology.2012; 18(2): 163.     CrossRef
  • 6,359 View
  • 63 Download
  • Crossref
Clinical Significance of the Correlation of Serum ProcollagenⅠand Ⅲ Propeptide Concentrations in Chronic Liver Diseases
Dong Il Park , Soong Hwan Lee , In Kyu Paik , Yong Hyeon Cho , Yun hu Cho , Byoung Hun kim , Dong Hoo lee
Korean J Hepatol 1996;2(1):13-20.
Background/Aims
Most liver diseases lead to a pathobiochemical reaction termed liver fibrosis. Hepatic fibrosis is not a uniform phenomenon and it comprises increased deposition of the liver connective tissue components(collagen, noncollagenous glycoprotein, proteoglycan) in the intercellular space, leading to disturbances of intrahepatic blood flow and hindrance of exchange processes between blood and cells, Fibrosis can be determined by morphological examination o f the liver, but this approach cannot be used to assess accurately the activity of collagen synthesis at any given point in time, Thus, the development of biochemical markers of hepatic fihrosis might allow a promising diagnostic approach for the identification and quantitation of this process, Aminoterminal procollagen III pn)peptide(PIIINP) and carboxytermina1 procollagen I propeptide(PICP) are known as the most widely used parameter for evaluating liver fibrosis, but it is diAicult to find previous report discribing the correlation ot each other. To elucidate the clinical significance of the corretation of PICP(x) and PIIINP(y) concentrations in patients with chronic liver diseases, radioimmunoassay was employed in this investigation. Methods:Sera tested were obtained from pathologically proven 43 patients;4 cases of fatly liver, 11 cases of chronic persistent hepatitis, 13 cases of chronic active hepatitis, l5 cases of liver cirrhosis. All the patients except 4 cases ot fatty liver were shown positivity of HBsAg. PICP and PIIlNP radioimmunoassay kits(Farrnos Diagnostica, Oulunsalo, Finland) wcre purchased for this study. Results:In the patients among the three groups of chronic active hepatitis, liver cirrhosis, chmnic persistent hepatitis, the correlations were significant in orders(y= - 10.27 +0.l3938x, r=0.92286, p=0.000007;y=-1.185+0.06611x, r=0.73656, p=0.001737;y=1.1174+0.03273x, r=0.56879, p=0.067849). Four cases of fatty liver reveal no signiticant correlation(y=4,8671- 0,0079x, r= 0.1959, p=0.804054). Conclusion:0n the basis of these data, we s st that the correlation of each showed a significant increase with heightening degree of inflammation, activity of diseases and fibrosis.
  • 2,908 View
  • 11 Download
Evaluation of Angiogenin Concentrations using ELISA in Sera from the Patients with Chronic Liver Diseases.
Kee Woon Kweon, Soong Hwan Lee, Seong Hee Lee, Hong Ju Kim, Chang Hwa Lee, Byoung Hun Kim, In Kyu Paik, Dong Il Park, Sung Soo Park, Dong Hoo Lee
Korean J Hepatol 1996;2(1):29-36.
Backgroud:Liver fibrosis by the progression of the chronic processes of the liver diseases induces deforrned microcirculations of the hepatic lobules. And this eventually resolted in portal hypertension. On the other hands, angiogenic stimu4nt factors are physiologically activated in order to repair the tissue damage. Overexpression of angiogenic factors, however, can stimulate neovascularization as in a fonnation of the tumor that liberates uncontrolled overgrowing of the tumor cells. Methods: To elucidate the dynamic changes of the serum concentration of angiogenin in chronic liver diseases, this study is intended to employ an ELISA in 44 pathologically proven patients. Quantikiae human angiogenin kit (R & D,systems Inc. Mmneapolis, MN) was used for this investigation. Results:Mean value and standard error of angiogenin concentration (ng/ml) of the sera was 238.92+ 50.95 in 5 cases of chronic persistent hepatitis, 184.47+ 12.75 in 6 cases of chronic active hepatitis, 131.36+ 10.99 in 19 cases of liver cirrhosis, and 211.03+ 19.08 in 14 cases of hepatocellular carcinoma, respectively. Serum angiogenin level in the liver cirrhosis was significantly lower than in chronic persistent hepatitis(p=0.00336), and than in chronic active hepatitis(p=0.018673). Angiogenin concentration in hepatocellular carcinomas was significantly higher than the level of the liver cirrhosis investigated(p=0.00569). Conclusions:These data support that persistent inflammatory insults in the chronic hepatitis were compensated by the elevation of angiogenin but complete fibrosis as in liver cirrhosis showed the depressed level. And emerging of the hepatocellular carcinoma is accompanied by the elevated stimuli of angiogenin for the neovascularization.
  • 58,544 View
  • 16 Download
A Study on the Efficacy and Safety of Dipheny - dimethyl - dicarboxylate in Patients with Chronic Liver disease
Hyoung Sik kim , Soo Taek Lee , Dae Gon kim , Deuk Soo Ahn
Korean J Hepatol 1996;2(1):54-60.
Background/Aims
The spectrum of clinical features of chronic liver disease bas wide range from asymptomatic cases to hepatic failure, The natural course and long-term prognosis of chronic liver disease also varies greately, and this diversity makes it diflicult to predict the clinical course of individual patient. The two majar approaches to the treatment of chronic liver disease are 1) directed toward the eradication of the virus and 2)designed to modulate cellular and humeral immunity. Progress has been made in the development of antiviral chernotherapeutic agents for hepatitis. But as yet no safe and reliably effective treatment or combination of treatrnents is available. In tkis study, we performed trial of diphenyl-dimethyl-dicarboxylate to evaluate the therapeutic effect and safety of it. Methods: The ciinical trials of DDB(complex capsule of diphenyl dimethyl dicarboxylate 7.5mg and polysorbate 80 1,5mg and polyethylene glycol 6000 66mg) were carried out in 30 patients with chronic liver disease for 6 months. All patients had abnormal liver function test ouer a period of 6 months. Results:In selected groups mean serum aspartate aminotransferase and alanine aminotrans- ferase dropped from pretreatment level of' 115.9+ 74.1 IU/L and 201.6+ 173.0 1U/L to posttreatment level of46.6+ 21.6 UU/L and 28.7- 15.4IU/L, respectively(p<0.01). There was no significant hernatological and biochemical change after administration of DDB. Untoward side effects were easily controlled by discontinuing the drugs, Conclusions:Administration of DDB(for 6 months) appears to be effective for decrement of transaminase level and safe for the treatment of patients with chronic liver disease.
  • 4,150 View
  • 102 Download
Clinical Significance of Serum Concentration of Intercelluar Adhesion Molecule - 1 in Patients with Acute and Chronic Liver Disease
Sung Shick Lim , Seok Ho Dong , Hyo Jong kim , Byung Ho Kim , Rin Chang , Joung Il Lee
Korean J Hepatol 1996;2(1):68-76.
Baekground/Aims:Recent studies, have examined the expression of adhesion molecules in liver inflammation, and the existence of soluble ICAM 1 in serum could be proved by ELISA. We maeasured s-ICAM 1 in patients with acute and ehronic liver disease to see the level of s-ICAM 1 can reflect degree of necroinflammation or progress of disease. Method:Serum levels of soluble forms of intercellular adhesion molecule 1(sIGAM 1) in 78 patients with acute and chronic liver disease including acute hepatitis B, CAH, C.'PH, post-necrotic and alcoholic liver cirrhosis, hepatoceliular carcinoma, toxic hepatitis were measured by enzyme-linked immunosorbent assays. Results.l> ICAM 1 semm levels in acute and chronic liver disease including acute hepatitis B(709.6+ 321.7 ng/L, p<0.001), C:AH(582.2+ 312.4 ng/L, p<0.001), CPH(357,8+ 135.0 ngL, p<0.044), postnecrotic livercirrhosis(716.2+ 348.0 ng/L, p<0.0001), alcoholic liver cirrhosis(763.3+ 48l.5 ng/L, p<0.009). Hepatocellular carcinoma(728.2+ 329.0 ng/L, p<0.002), toxic hepatitis(817.3+ 324.4 ng/l, p<0.0001) were signiticantly higher than that of healthy controLs(234.5+ 67.5 ng/L). 2> In comparison with CPH we found significantly increased ICAM- 1 serum levels in CAH.(p=0.027) A significant correlation was found between the ICAM-1 serum level and the histologically graded inflammatory activity in CAH. 3>No correlation was found be1ween the ICAM l serum level aml the Child- Pugh classification in liver cirrhosis. 4>In comparison with chronic hepatitis we found signitcantly increased 1CAM 1 serum levels in liver cirrhosis(p = 0.001) , and in hepatocellular carcinoma(p = 0.0001), Conclusion:Soluble ICAM I serum level correlated well with ongoing necrointlammatory activity in acute and chronic hepatitis and also slCAM 1 can reflect disease severity in various chronic 1iver disease groups.
  • 2,818 View
  • 17 Download
Changes of Epidermal Growth Factor in Sera among the Patients with Chronic Hepatitis , Cirrhosis and Hepatocellular Carcinoma
Yong Hyeon Jo , Byeong Hoon Kim , Hong Ju Kim , Yeong Jung Cho , Je Lee , Jung Hae Choi , Seong Kyu Yang , Yong Koel Yoo , Kee Woon Kweon , Dong Hoo Lee
Korean J Hepatol 1997;3(1):29-39.
Background/Aims
. Epidermal growth factors (EGF) is known to activate mitogen activated protein kinase (MAP kinase) in hepatocytes by the route of both Raf-dependent and Raf-indefendent pathways. And this is likely to play important role in normal liver cell growth and regeneration. EGF is also reported as a potent mitogen and one of the angiogenic factors. To elucidate the dynamic changes of the serum concentration of epidermal growth factor in chronic liver disease and its correlation with role of EGF and mechanism of tumor development, this study is intended to employ an ELISA in 38 biopsy-proven cases. Methods '. Sera taken out of 5 patients with chronic persistent hepatitis. 4 patients with chronic active hepatitis, 19 patients with liver cirrhosis, 10 patients with hepato- cellular carcinoma that pathological diagnosis was proven later were tested for EGF employing Quantikine ELISA Kits (R & D Systems Inc. Minneapolis, MN). The statistical analysis was evaluated by student's t-test. Results . EGF concentration was 253.33+ 69.5pg/ml(Mean+ SE) in hepatocellular carcinoma, 246.60+ 91.19pg/ml(Mean+ SE) in chronic active hepatitis, 222.71+ 115.97pg/ml (Mean+ SE) in chronic persistent hepatitis, 141.15+ 23.12pg/ml(Mean+ SE) in liver cirrhosis in orders. Serum EGF concentration in hepatocellular carcinoma was significantly higher than that in liver cirrhosis(p value=0.021695). However, comparing to the remaining other groups, no significant difference was found. Conclusion .' These results support that the reconstruction of the capillary networks in liver cirrhosis resplts in down-regulation of the EGF in comparison to chronic hepatitis. But it is suggested that revaluation of EGF stimulates MAP kinase activity eventually playing in tumorigenesis of the liver with neoangiogenesis.
  • 2,937 View
  • 14 Download
Serum Phospholipase A2 Activities in Patients with Chronic Liver Disease
Jong Myung Lee , Young Oh Kweon , Nung Soo Kim
Korean J Hepatol 1997;3(2):170-178.
Background
/Purpose: Phospholipase A (PLAq) is an rate-limiting enzyme hydrolyzing arachidonic acid from the sn-2 position of membrane phospholipids. In vitro studies demonstrated that the enzyme could be secreted into extracellular mileu by pro-inflammatory cytokines and endotoxin which were reported to have important roles in chronic liver diseases. This study was performed to know whether the enzyme is involved in the pathophysiology of the diseases. Methods: The subjects were composed of 24 patients with chronic hepatitis B, 26 patients with liver cirrhosis and 14 healthy individuals. The PLAp activities wem measured in the sera of the subjects by detecting radioactivity of "C-fatty acid hydrolyzed from "C-labeled phosphotadylethanolamine by the enzyme. Results: The activities of PLA were increased in the patients with chronic liver diseases, especially in the chronic hepatitis B patients with acute exacerbation and in the decompensated cirrhosis patients. Furthermore, their activities were closely related with the levels of transaminase in hepatitis group and with the levels of serum albumin in cirrhosis group, respectively. Conclusions: These results suggest that extracellular PLA might be involved in the exacerbution and progression of the chronic liver diseases.
  • 9,571 View
  • 12 Download
Distinct Expressions of TGF - α among Chronic Hepatitis , Liver Cirrhosis , and Hepatocellular Carcinoma
Byeong Moo Yoo , Sung Soo Park , Dong Hoo Lee , Jung Dal Lee
Korean J Hepatol 1997;3(4):316-328.
Background
/Aim: Transforming growth factor-a(TGF-a) is a polypeptide cytokine related to cell proliferation and transformation. TGF- a binds to EGF receptor and stimulating DNA synthesis in liver cell. The hepatitis B virus (HBV) by itself is also believed to play a role in the hepatic carcinogenesis. Recently, it was reported that TGF- a and HBV were synergistic in action with rapid appearance of hepatocelluar carcinoma in bitransgenic mice. Although TGF- a is thought to play an important role in hepatocarcinogenesis, its expression during the natural history of HBV hepatitis was poorly understood. This investigation was performed to elucidate the dynamic changes and distinct immunohistochemical staining patterns in the course of chronic HBV hepatitis with specific reference to hepatocelluar carcinoma and to explain the role of TGF- a in the pathogenesis of hepatocelluar carcinoma. Materials/Methods: Employing TGF- a monoclonal antibody, signal detection was carried out by peroxidase-conjugated streptavidin in deparaffinized liver tissue sections taken from HBsAg positive patients. All of the liver tissue sections were proven HBV DNA positive by in situ hybridization. Immunohistochemical staining was performed in the tissue sections obtained from four normal controls, six from patients with chronic persistent hepatitis, five with chronic active hepatitis, eight with liver cirrhosis and eleven with hepatocellular carcinoma. Results: The patterns of TGF- a immunoreactivity were cytoplasmic-grain types in normal controls and chronic persistent hepatitis, honeycomb types in chronic active hepatitis, occasional cytoplasmic-flooding types in liver cirrhosis, and cytoplasmic-grape types in hepatocellular carcinoma. A Shapiro-Wilk W test for frequency table analysis for the expression of TGF- a in these different disease groups was statistically significant. Conclusion: These data suggest that step-wise distinct expression of TGF-a enhancement in HBV associated chranic liver diseases which eventually resulted in the development of hepatocellular carcinoma were conceivably due to dysregulation of liver cell cycles by both HBV and TGF- a during the persistent repetition of cell cycles. (Korean J Hepatol 1997;7:316 328)
  • 2,791 View
  • 12 Download
A Prospective Study of Therapeutic Effect of 6 Months Trial with Lamivudine in Patients with Chronic Viral Hepatitis B
Chang Woo Gham,Soong Hwan Lee,Seung Woo Nam,Seung Woo Nam,Byung Joo Roh,Dong Hoo Lee
Korean J Hepatol 1999;5(4):282-290.
Background/Aims
The purpose of this study was to evaluate the effectiveness of lamivudine treatment in patients with chronic liver disease caused by chronic infection of hepatitis B virus (HBV). Methods: Thirty-five patients with chronic infection of HBV were included in this study who were diagnosed at Hanyang University Hospital from January 1998 to January 1999. They received 150mg of lamivudine per oral once daily for 6 months with follow-up of liver function test, serum HBV DNA and serologic markers for hepatitis B virus every two months. Lamivudine was well tolerated. Eight patients underwent liver biopsies before entering the study and follow-up biopsies were done at 5 patients. Results: Out of all 35 patients, chronic hepatitis patients histologically confirmed were 8, chronic hepatitis patients clinically diagnosed were 25 and liver cirrhosis patients clinically diagnosed were 2. The mean age was 35.7 years. Male-female ratio was 2.2:1. There was no hepatitis B surface antigen (HBsAg) negative seroconversion. The HBeAg loss rate was 26.9%(7/26) and HBeAg seroconversion rate was 10.7%(3/28) at the end of follow-up. Ten patients were anti-HBe positive prior to treatment, 3 of them became anti-HBe negative at the end of follow-up. Five patients underwent follow-up liver biopsies, in which histologic improvements were shown in 4 cases. Serum replicative HBV DNA by bDNA assay was decreased in all patients and HBV DNA was undetectable in 52.9%(9/17) at the end of treatment. Out of the 15 patients with abnormal alanine aminotransferase (ALT) levels at baseline, ALT level in 7 patients(46.7%) was normalized at treatment completion. Pretherapy ALT level was the only predictive factor for loss of HBeAg by stepwise logistic regression analysis(odds ratio : 1.0208) (95% Confidence Interval : 1.0023 ∼ 1.0396) (p value=0.0271). Conclusions: Lamivudine induced sustained suppression of HBV replication during treatment in all patients. In treating patients with lamivudine, who had chronic liver disease due to chronic infection of HBV, the improvement of liver function test and suppression of viral replication appeared early and was sustained during the 6months treatment. This, in turn, may induce histological improvement as well. Pretherapy ALT level was the only predictive determinant for HBeAg loss during lamivudine therapy, and that should be kept in mind in selecting patients for treatment. (Korean J Hepatol 1999;5:282-290)
  • 2,784 View
  • 11 Download
Efficacy of Lamivudine in Patients with HBeAg-Negative and HBV DNA-Positive Chronic Liver Disease
Hye Seung Yoo,Han Joo Lee,Young Hwa Jung,Young Sang Lee,Dong Jin Seo
Korean J Hepatol 2000;6(4):488-494.
Background/Aims
The aim of this study was to evaluate the efficacy of lamivudine in patients with HBeAg-negative and HBV DNA-positive chronic liver disease. Methods: Twenty-four chronic liver disease patients were enrolled whose serology had common characteristics of HBeAg (-), and anti-HBe (+) but HBV DNA (+). All had elevated alanine aminotransferase (ALT) levels. 150mg of lamivudine was given orally once daily for more than 6 months. The goal of this treatment was the elimination of HBV DNA in serum and normalization of ALT level. Once HBV DNA disappearance and ALT normalization were observed, lamivudine was continued for two additional months. HBeAg, anti-HBe, HBV DNA and ALT were followed up every 1-2 month during, and after, treatment. Results: Median duration of treatment was seven months. HBV DNA became undetectable after a median one month of treatment and ALT activity was normalized in all 24 patients within six months. Among the sixteen patients who were followed for more than 12 months after cessation of treatment, six relapsed. The cumulative relapse rate at 12 months was 37.5%. Conclusion: Lamivudine suppresses HBV replication effectively and normalizes serum ALT in patients with HBeAg-negative and HBV DNA-positive chronic liver disease. The relapse rate after cessation of treatment seems to be relatively low.
  • 2,759 View
  • 13 Download
Implications of Serum Levels of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Chronic Liver Diseases and Hepatocellular Carcinoma
Sung Jae Yoo, M.D, Sung Moon Jung, M.D, Jong Gwang Kim, M.D, Jin Ok Lee, M.D, Yong Whan Song, M.D, Chul Ju Han, M.D, Sook-Hyang Jung, M.D, You Cheoul Kim, M.D, Chang-Min Kim, M.D, Jhin Oh Lee, M.D, Young Joon Hong, M.D* and Seok Il Hong, M.D*
Korean J Hepatol 2001;7(1):47-54.
Background/Aims
Angiogenesis occurs in response to tissue damage, and is of vital importance for tumor growth and metastasis. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are potent angiogenic factors, and have been suggested to be useful diagnostic markers in certain hypervascular tumors. However, little is known of serum bFGF and VEGF in patients with hepatocellular carcinoma (HCC). We attempted to measure serum bFGF and VEGF in patients with chronic liver diseases (CLD) and HCC to assess their pathogenetic role and usability as tumor markers. Methods: Serum bFGF and VEGF were measured in 8 patients with chronic hepatitis (CH), 15 patients with liver cirrhosis (LC), and 49 patients with HCC. bFGF was measured in 33, and VEGF was measured in 50, healthy blood donors. Results: Serum bFGF was 3.8±1.9, 2.0±1.4, 4.2±6.0, 17.4±30.0 pg/mL in normal control, CH, LC, HCC, respectively. The serum bFGF level was significantly increased in patients with HCC when compared with normal control or patients with CLD. No difference, however, was observed in serum VEGF levels among the four groups. The serum levels of bFGF and VEGF were not significantly different in patients with HCC according to tumor type, size and stage. Serum bFGF showed good sensitivity (90%), specificity (87%), and positive predictive value (94%) in differentiating patients with HCC from those with CLD at the cut-off value of 4.6 pg/mL. Conclusions: bFGF might play a role in the growth of HCC and its serum level might be used as a tumor marker. On the other hand, serum VEGF does not seem to be an adequate tumor marker.(Korean J Hepatol 2001;7:47-54)
  • 2,918 View
  • 20 Download
Clinical Significance of Autonomic Neuropathy in Liver Cirrhosis
Jae Hong Park, M.D., Sung Woo Jeon, M.D., Min Kyu Jung, M.D., Jong Hyub Lee, M.D., Chang Min Cho, M.D., Won Young Tak, M.D., Young Oh Kweon, M.D., Sung Kook Kim, M.D., Yong Hwan Choi, M.D., Joon Mo Chung, M.D., Ki Soo Park, M.D.*
Korean J Hepatol 2001;7(2):153-161.
Background/Aims
Autonomic neuropathy is not rare in patients with liver cirrhosis but little is known about the mechanisms and clinical characteristics of it. We evaluated the relationship between the severity of liver disease and that of autonomic neuropathy.Methods:Sixty patients with liver cirrhosis (age 53±8.4, mean±SD) were studied. Liver function and prothrombin time were tested and an ultrasonography or CT scan was performed. Liver function reservoir was classified according to Child-Pugh score for all patients. Heart rate variations in response to deep breathing, to Valsalva maneuver, and to orthostatism were also measured and were expressed by E/I index, Valsalva index, and Posture index, respectively. The prevalence was estimated and divided into early involvement and definite involvement using each index. The correlation between the severity of the liver disease and that of autonomic neuropathy was also studied.Results:Evidence of autonomic neuropathy was found in 68.3% (41); early involvement 46.7% (28), and definite involvement 21.7% (13), respectively. The prevalence of autonomic neuropathy was similar in alcohol induced, and virus induced, liver disease (84.6% vs 63.8%). Child-Pugh score showed inverse correlation with E/I index (r=-0.38, p<0.01) and Valsalva index (r=-0.34, p<0.05). On multiple logistic regression analysis, cardiovascular autonomic neuropathy was related to the serum albumin level (odds ratio 0.063, 95% CI). Conclusion:In liver cirrhosis the prevalence and the severity of cardiovascular autonomic dysfunction are related to the severity of hepatic dysfunction (Child-Pugh score). It is possible that this complication may be of prognostic significance in patients with liver cirrhosis.(Korean J Hepatol 2001;7:153-161)
  • 3,410 View
  • 15 Download